GENFIT announces that Labcorp’s NASHnext, based on its NIS4 non-invasive diagnostic technology for identifying at-risk MASH, is launching via the Labcorp OnDemand platform

▤ Summary

GENFIT says Labcorp has launched NASHnext through the Labcorp OnDemand platform. The test uses GENFIT’s NIS4 non-invasive diagnostic technology to help identify patients at risk of MASH. Labcorp OnDemand expands access by letting patients order the test online with physician oversight and then review results digitally. GENFIT positions the launch as a way to reach a broader U.S. population and support earlier diagnosis, treatment decisions, and future reimbursement-driven adoption.

▦ Linked Companies